Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 9;14:20930. doi: 10.1038/s41598-024-71419-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — Serum antibody analysis during convalescence. (A) Comparison of IgG anti-nucleocapsid protein (OD) and correlation under anti-N concentration and days post symptoms; (B) Comparison of IgG anti-Spike protein (AU/mL) and correlation between anti-S concentration and days post symptoms. The cutt-off 1.280 AU/mL was highlighted to demonstrate the participants that were eligible to convalescent plasma donation in D30 (n = 30/62 [48.4%]), D60 (n = 20/48 [41.7%]) and D90 (n = 14/47 [29.8%]); (C) Percentage of participants with a qualitative (pos/neg) antibody production among study period, based on anti-S immunochromatographic test, and CMIA anti-S and anti-N, with absolute and relative values on table below; (D) Fold change comparison between D60/D30, D90/D30 and D90/60 IgG anti-S antibody concentration, using quantitative result from patients with all follow-up (n = 45). Statistical analysis was performed with One-Way ANOVA followed by Turkey’s Multiple comparison test, considering significative when p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.